Identification of Novel Hypoxia Subtypes for Prognosis Based on Machine Learning Algorithms
Jiawei Wang1, Tuo Li2, Songquan Wei3
1Department of Obstetrics and Gynecology, Nantong Maternity and Child Health Care Hospital Affiliated to Nantong University, Nantong 226018, Jiangsu Province, China.
Journal of Oncology
|September 22, 2022
Summary
Two distinct hypoxia subtypes were identified in ovarian cancer (OC). Hypoxia subtype 2 is linked to poorer clinical outcomes and altered tumor microenvironments, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Hypoxia, a state of reduced oxygen, is common in solid tumors, including ovarian cancer (OC).
- Tumor hypoxia significantly influences cancer progression and treatment response in OC.
- Understanding hypoxia's role is crucial for developing effective OC therapies.
Purpose of the Study:
- To identify and characterize distinct hypoxia-related subtypes in ovarian cancer.
- To investigate the molecular mechanisms and clinical implications of these hypoxia subtypes.
- To explore the association between hypoxia subtypes and the tumor microenvironment (TME) in OC.
Main Methods:
- Consensus clustering analysis of hypoxia-related genes in The Cancer Genome Atlas (TCGA) ovarian cancer cohort.
- Differential gene expression (DEG) analysis, gene ontology, mutation profiling, and immune cell infiltration analysis.
- Classification of 377 OC patients into two identified hypoxia subtypes.
Main Results:
- Two distinct hypoxia-related subtypes were identified in ovarian cancer.
- Hypoxia subtype 2 was associated with significantly poorer clinical outcomes.
- Reduced expression of CLIP2 and SH3PXD2A was observed in OC tissues; subtypes correlated with TME characteristics.
Conclusions:
- The study confirms two complex and heterogeneous hypoxia subtypes in ovarian cancer.
- Quantitative analysis of these subtypes enhances understanding of OC's TME.
- Findings may guide the development of more targeted and effective treatment strategies for ovarian cancer.


